Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase

被引：10
|
作者：
Bradshaw, D.
Malik, S.
Booth, C.
Van Houtte, M.
Pattery, T.
Waters, A.
Ainsworth, J.
Geretti, A. M.
机构：
[1] Royal Free Hosp, Dept Virol, London NW3 2QG, England
[2] UCL, Sch Med, Royal Free Hosp, London W1N 8AA, England
[3] Virco BVBA, Mechelen, Belgium
[4] N Middlesex Hosp, Dept HIV Med, London, England
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 12期
关键词：
D O I：
10.1128/AAC.00687-07
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We describe an unusual pathway of human immunodeficiency virus type 1 reverse transcriptase resistance during therapy with tenofovir-emtricitabine, characterized initially by the mutations K70E and M184V and later by K70G and M184V, with the two mutations coexisting on the same viral genome. Phenotypic resistance to lamivudine, emtricitabine, abacavir, didanosine, and tenofovir was observed, whereas susceptibility to zidovudine and stavudine was preserved.
引用
收藏
页码：4489 / 4491
页数：3
相关论文
共 50 条
  • [11] The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1
    Boyer, PL
    Sarafianos, SG
    Arnold, E
    Hughes, SH
    JOURNAL OF VIROLOGY, 2002, 76 (07) : 3248 - 3256
  • [12] The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis
    Götte, M
    Arion, D
    Parniak, MA
    Wainberg, MA
    JOURNAL OF VIROLOGY, 2000, 74 (08) : 3579 - 3585
  • [13] The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates
    Diallo, K
    Brenner, B
    Oliveira, M
    Moisi, D
    Detorio, M
    Götte, M
    Wainberg, MA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2376 - 2379
  • [14] A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
    Hertogs, K
    Bloor, S
    De Vroey, V
    Van den Eynde, C
    Dehertogh, P
    Van Cauwenberge, A
    Stürmer, M
    Alcorn, T
    Wegner, S
    Van Houtte, M
    Miller, V
    Larder, BA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) : 568 - 573
  • [15] Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity
    Diallo, K
    Marchand, B
    Wei, X
    Cellai, L
    Götte, M
    Wainberg, MA
    JOURNAL OF VIROLOGY, 2003, 77 (16) : 8621 - 8632
  • [16] The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus
    Whitney, JB
    Oliveira, M
    Detorio, M
    Guan, YJ
    Wainberg, MA
    JOURNAL OF VIROLOGY, 2002, 76 (17) : 8958 - 8962
  • [17] HIV-1 reverse transcriptase M184V and R212 K combined mutations conconfer phenotypic resistance to stavudine
    Nicastri, E
    Sarmati, L
    Parisi, SG
    D'Ettorre, C
    Narciso, F
    Vullo, V
    Andreoni, M
    AIDS, 2000, 14 : S112 - S112
  • [18] Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro
    Miller, MD
    Anton, KE
    Mulato, AS
    Lamy, PD
    Cherrington, JM
    JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01): : 92 - 100
  • [19] Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro
    Drosopoulos, WC
    Prasad, VR
    JOURNAL OF VIROLOGY, 1998, 72 (05) : 4224 - 4230
  • [20] Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type I by various nucleoside antiretroviral agents in tissue culture
    Petrella, M
    Oliveira, M
    Moisi, D
    Detorio, M
    Brenner, BG
    Wainberg, MA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (11) : 4189 - 4194
12345